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Abstract
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide. Underlying chronic liver disease
has been associated with an increased risk of developing HCC. This study is a review of the current literature regarding the
diagnosis, prognostic significance, and role of treating underlying liver disease in patients who are at risk of primary liver cancer.
Relevant peer review of the English literature between 1980 and 2017 within PubMed and the Cochrane library was conducted for
scientific content on current advances in managing chronic liver diseases and the development of hepatocellular carcinoma.
Hepatitis C virus, hepatitis B virus (HBV), nonalcoholic steatohepatitis, autoimmune hepatitis, hereditary hemochromatosis,
Wilson disease, primary biliary cirrhosis, a 1-antitrypsin deficiency, and certain drugs lead to an increased risk of developing HCC.
Patients with underlying liver disease have an increased incidence of HCC. Hepatitis C virus, HBV, and hemochromatosis
can directly lead to HCC without the presence of cirrhosis, while HCC related to other underlying liver diseases occurs in
patients with cirrhosis. Treating the underlying liver disease and reducing the progression to cirrhosis should lead to a decreased
incidence of HCC.
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Introduction
Hepatocellular carcinoma (HCC) is the third leading cause of
cancer-related deaths worldwide and develops at a rate of 3% to
4% in patients with liver disease.1,2 Hepatocellular carcinoma
typically occurs in the setting of chronic liver disease and
cirrhosis. Hepatitis C virus (HCV), hepatitis B virus (HBV),
and hereditary hemochromatosis can directly lead to HCC,
while HCC related to other underlying liver diseases is linked
to the development of cirrhosis.
These other underlying liver diseases that cause progression
to cirrhosis include nonalcoholic steatohepatitis, autoimmune
hepatitis (AIH), primary sclerosing cholangitis, Wilson
disease, primary biliary cirrhosis (PBC), and a 1-antitrypsin
(A1ATD) deficiency. Certain drugs and toxins are also risk
factors for the development of HCC. The increased incidence

of these underlying liver diseases has contributed to nearly
double the age-adjusted incidence rate of HCC in the United
States in recent decades.1
Several treatment options have emerged for the management of HCC. These include systemic chemotherapy, hormonal
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therapy, targeted therapy, immunotherapy, locoregional therapy, surgical resection, and liver transplant. The focus has
shifted toward the treatment of the malignancy without concern
of the underlying etiology.3 The aim of this review is to discuss
the underlying liver diseases associated with primary liver cancer and discuss the role of treatment of the primary liver disease
as it affects the development of HCC.

Hepatitis C Virus
Chronic HCV is now the most common cause of infectionrelated death worldwide and approximately 130 to 170 million
individuals are currently infected.4 Untreated, chronic HCV
infection can cause deterioration of liver function and leads
to hepatic failure. The course of the liver damage is unpredictable and can range from stable liver function to sudden decompensated hepatic failure.5
Hepatitis C virus is the dominant cause of HCC in the
United States and Europe. As a result, the relationship
between HCV infection and the development of HCC has
been closely studied.6,7 It is the persistent inflammation and
destruction of hepatocytes that most significantly leads to
carcinogenesis. Cell turnover causes poorly differentiated
hepatocytes to proliferate and develop into dysplastic
nodules and HCC. The degree of inflammation in the liver
of patients with HCV also correlates with prognosis once
HCC is diagnosed. This makes treatment of underlying HCV
critical to outcomes.
There are currently 6 major genotypes (1, 2, 3, 4, 5, and 6) of
HCV. Genotype 1, specifically 1a, is the most common in the
United States, as it represents 58% of the HCV population.
Genotype 1b represents an additional 21%, followed by genotype 2 at 15%, and genotype 3 at 5% of the HCV population.
Traditionally, genotypes have played a major role in the selection of treatment options.8 With the recent surge in newer
noninterferon-based therapies, most commonly referred to as
direct-acting agents (DAAs), specific medications are chosen
based on the genotype, presence or absence of cirrhosis, and
presence or absence of NS5A resistance–associated variants.
However, there is a now a pan-genotypic DAA, sofosbuvir/
velpatasvir, that has been approved for the treatment of genotypes 1 through 6, which can have implications worldwide
given the decreased need for expensive laboratory testing and
simplicity of treatment.9 Although current head-to-head studies
are ongoing, it appears that achieving sustained virologic
response (SVR) is the most important factor for decreased risk
of HCC and improvement of outcomes.
A recent meta-analysis of 30 different studies performed by
Morgan et al10 determined that the treatment of HCV strongly
reduced the risk of HCC development. Patients who achieve
SVR have a lower risk of developing HCC than those who were
treated but did not achieve an SVR. Even in the setting of
established underlying HCC secondary to HCV, a newly published study found improved overall survival in patients with
SVR than those with continued HCV-positive RNA virus loads
(15 months vs 9.2 months).11
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Hepatitis B Virus
An estimated 240 million people worldwide have chronic
hepatitis B (CHB), and it is the dominant cause of HCC
worldwide.12 The risk of HCC among patients with HBV is
2% to 5%, and it can develop even in the absence of cirrhosis.
However, 70% to 90% of patients with HBV who develop HCC
will have cirrhosis. Factors associated with an increased risk
of HCC include male sex, increased age, and certain genetic
polymorphisms. Because of the association between HBV and
HCC, screening for HCC is critical in these patients.
Several studies suggest that the risk of developing HCC is
reduced by approximately 50% to 60% following treatment.
Lin et al13 did find a statistically significant risk reduction of
HCC with the treatment of underlying CHB (hazard ratio [HR]:
0.31; 95% confidence interval [CI]: 0.15-0.66; P ¼ .002). The
importance of treating immune-active CHB for overall reduction in HCC is further supported by the completion of a
35-study meta-analysis to include 59 201 participants by Lok
et al.14 Current antiviral therapies aim to suppress HBV replication and reduce viral load, cause the loss of hepatitis B e
antigen, and cause the loss of hepatitis B surface antigen. The
presence of these antigens has been associated with an
increased risk of developing HCC. Practice guidelines set by
the American Association for the Study of Liver Diseases
(AASLD) recommend the treatment of CHB for patients with
immune-active phase disease in an effort to reduce cirrhosis,
decompensated liver disease, and HCC. Patients with immunetolerant CHB are at low risk, and treatment is not recommended per the AASLD guidelines.15

Nonalcoholic Fatty Liver Disease
Nonalcoholic fatty liver disease (NAFLD) is subdivided into
nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH). In NAFL, hepatic steatosis is present without
evidence of inflammation, whereas in NASH, hepatic steatosis
is associated with hepatic inflammation that histologically is
indistinguishable from alcoholic steatohepatitis.16 Incidence of
NAFLD is reported to be between 6% and 35% worldwide.17
The management of NAFLD is based on lifestyle modification,
with the goal of reversing factors that can lead to disease progression. Weight loss of 3% to 5% of total body weight has
been proven to improve steatosis, and further weight loss of up
to 10% has been beneficial in reducing and even reversing
inflammation and fibrosis. Medical management of hyperlipidemia, diabetes mellitus, and obesity has also been linked to
improved prognosis.18
Current research suggests that NAFLD is a preneoplastic
condition with overall increased mortality and a high risk of
developing cirrhosis with subsequent progression to HCC.1,1922
Hepatocellular carcinoma can also develop in the absence of
cirrhosis in patients with NAFLD, making it an increasingly
difficult disease to manage. The progression of NAFLD to cirrhosis and HCC has been linked to adiposity and insulin dysregulation, suggesting a dynamic process affected by a multitude
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of factors.18,23 It is estimated that 20% of all patients with
NAFLD will develop cirrhosis, and 45% of those patients will
become decompensated 10 years from the time of cirrhosis
diagnosis.
Treatment options for NAFLD are limited. Weight loss of
10% of body weight and exercise can improve steatosis; however, the ideal diet and structured exercise program are not
well known. For those who cannot lose weight, bariatric surgery has been suggested as an option, given its ability to
improve and even reverse NAFLD.18 Vitamin E at 800 IU/d
should be considered a first-line therapeutic option for nondiabetic patients without cirrhosis, as it has been associated
with an improvement in liver histology in this select group.
Other therapies such as ursodeoxycholic acid, metformin, and
o-3 fatty acids have not consistently been proven to improve
steatosis and are thus not indicated as treatment options of
NAFLD.16 Given its growing incidence and new treatment
options for HCV, it is predicted that the most common indication for liver transplantation within the next 30 years will
become NAFLD-induced cirrhosis.23

Autoimmune Hepatitis
Autoimmune hepatitis is characterized by 4 major factors:
chronic liver inflammation, interface hepatitis seen on histology, hypergammaglobulinemia, and the production of autoantibodies-like antinuclear antibodies, anti-smooth muscle
antibodies, and liver/kidney microsomal antibodies.24-26
Early diagnosis and treatment is critical to avoid progression
to cirrhosis and hepatic decompensation. Treatment can be
initiated with immunosuppressive medications, with the end
points being the normalization of transaminases, reduction in
hypergamaglobulinemia, and improvement of histology.
Contradictory to the long-held belief that the risk of
malignancy in AIH is negligible, the risk of both hepatic and
extrahepatic malignancies still exists. This is particularly true
in the setting of cirrhosis.25,27 The relative rarity of AIH
makes it difficult to determine the incidence of HCC, but
studies have shown that malignancy can arise as a consequence of both the underlying liver disease and of prolonged
immunosuppression for treatment.25,28 Major risk factors for
HCC in AIH include cirrhosis for at least 10 years with
decompensation manifested as portal hypertension, immunosuppression for at least 3 years, and male sex. Therapeutic
options for HCC in AIH vary according to the size and number of lesions as well as the presence of metastatic disease,
but when liver transplantation is an option, it tends to be
curative for both AIH and HCC.29,30

Other Etiologies
Several other underlying liver diseases can lead to the development of cirrhosis and ultimately HCC. Hereditary hemochromatosis is an autosomal recessive disease in which a progressive
accumulation of iron can cause congestive heart failure, diabetes, and cirrhosis.31 The prevalence of homozygous hereditary
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hemochromatosis is estimated between 0.26% and 1.89%.32
Patients with hereditary hemochromatosis with known cirrhosis
are at a nearly 20-fold increased risk of developing HCC.33 Early
detection and treatment of hemochromatosis will significantly
reduce the morbidity and mortality.
Wilson disease is a rare, autosomal recessive metabolic disorder with an incidence estimated at 1 in 40 000. Although the
risk of HCC does not appear to be as great as it is in hereditary
hemochromatosis, the risk of liver damage and subsequent progression to HCC have been well-documented. The extent of
variability in presentation and pathologic features can be attributed to the heterogeneous nature of genetic variability. Copper
overload plays a key role in liver injury and development of
cirrhosis, but whether or not there is a direct connection to the
oncogenic process is yet to be determined. Prevention of HCC
is dependent on early diagnosis and treatment to prevent longterm liver damage.34
Primary biliary cirrhosis is an autoimmune progressive cholestatic disease. It initially causes ductal damage by forming
granulomas and ultimately leads to the development of cirrhosis. There is conflicting data about the prevalence of HCC in
the setting of PBC; however, it has been observed that patients
with late stages of PBC (III or VI) had an increased incidence
for HCC at 11.1%.35
Alpha 1-antitrypsin deficiency causes an abnormal deposition
of excessive abnormal a 1-antitrypsin protein in the liver and can
ultimately lead to the development of cirrhosis. It is suggested
that patients with A1ATD have a higher incidence of HCC and
this development can be seen in the absence of cirrhosis.36-38
Drugs and toxins may also contribute to the pathogenesis of
HCC. This progression involves the development of druginduced liver injury (DILI) that ultimately leads to inflammation, fibrosis, and cirrhosis. The most common classes of medications causing liver injury are antibiotics, antiepileptics
nonsteroidal anti-inflammatory agents, immune modulators, and
various herbal and dietary supplements. In general, DILI that
progresses to liver failure has a very poor prognosis.39

Conclusion
The underlying etiology of liver disease plays a significant
role in overall prognosis of primary liver cancer. Although it
is the rapid progression to cirrhosis that appears to increase
the incidence of HCC for patients with underlying liver disease, it is important to understand HCV, HBV, and hereditary
hemochromatosis can lead to the development of HCC without progression to cirrhosis. Treatment and management of
underlying liver disease should be aggressively pursued in
efforts to reduce progression to cirrhosis, which should lead
to a reduced incidence of HCC.
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